A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and MK 3475 in Subjects With Advanced Renal Cell Carcinoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Pazopanib (Primary) ; Pembrolizumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline; Novartis
- 06 Jun 2017 Preliminary safety and efficacy results (n=35) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 11 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 17 Mar 2017 Planned End Date changed from 1 Aug 2021 to 9 Feb 2019.